Clearside Biomedical, Inc. (NASDAQ:CLSD) will announce its earnings results on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The company had revenue of $0.13 million for the quarter. On average, analysts expect Clearside Biomedical to post $-2.06 EPS for the current fiscal year and $-2.22 EPS for the next fiscal year.

Shares of Clearside Biomedical, Inc. (CLSD) opened at 7.02 on Tuesday. Clearside Biomedical, Inc. has a one year low of $5.44 and a one year high of $24.73. The firm’s 50-day moving average is $7.92 and its 200-day moving average is $7.92. The company’s market cap is $177.86 million.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/10/31/clearside-biomedical-inc-clsd-to-release-quarterly-earnings-on-tuesday.html.

In other news, Director Clay Thorp sold 4,500 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $8.02, for a total transaction of $36,090.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gerald D. Cagle purchased 5,000 shares of Clearside Biomedical stock in a transaction dated Friday, August 11th. The shares were purchased at an average price of $7.08 per share, for a total transaction of $35,400.00. Following the completion of the acquisition, the director now owns 15,941 shares of the company’s stock, valued at approximately $112,862.28. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 7,100 shares of company stock worth $50,170 and have sold 132,000 shares worth $1,038,110. Insiders own 20.90% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its holdings in shares of Clearside Biomedical by 84.8% during the second quarter. California State Teachers Retirement System now owns 36,600 shares of the company’s stock worth $333,000 after purchasing an additional 16,800 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Clearside Biomedical by 21,620.7% during the second quarter. The Manufacturers Life Insurance Company now owns 17,811 shares of the company’s stock worth $162,000 after purchasing an additional 17,729 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Clearside Biomedical by 99.7% during the second quarter. State Street Corp now owns 259,599 shares of the company’s stock worth $2,367,000 after purchasing an additional 129,621 shares during the last quarter. Institutional investors own 52.45% of the company’s stock.

CLSD has been the topic of a number of recent analyst reports. TheStreet cut Clearside Biomedical from a “c-” rating to a “d” rating in a research report on Friday, August 11th. Cowen and Company restated a “buy” rating on shares of Clearside Biomedical in a report on Wednesday, October 25th. Zacks Investment Research cut Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Monday, July 17th. Finally, ValuEngine cut Clearside Biomedical from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $18.33.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.